Eli Lilly and Company or Amneal Pharmaceuticals, Inc.: Who Invests More in Innovation?

Eli Lilly's R&D investment dwarfs Amneal's by 30 times.

__timestampAmneal Pharmaceuticals, Inc.Eli Lilly and Company
Wednesday, January 1, 20141067350004733600000
Thursday, January 1, 20151368700004796400000
Friday, January 1, 20162047470005243900000
Sunday, January 1, 20171919380005281800000
Monday, January 1, 20182104510005051200000
Tuesday, January 1, 20192022870005595000000
Wednesday, January 1, 20201905850006085700000
Friday, January 1, 20212095630007025900000
Saturday, January 1, 20222000460007190800000
Sunday, January 1, 20231677780009313400000
Monday, January 1, 202414271000000
Loading chart...

In pursuit of knowledge

Innovation Investment: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, innovation is key to staying ahead. Eli Lilly and Company and Amneal Pharmaceuticals, Inc. are two prominent players, each with a distinct approach to research and development (R&D) investment. Over the past decade, Eli Lilly has consistently outpaced Amneal, investing nearly 30 times more in R&D annually. From 2014 to 2023, Eli Lilly's R&D expenses surged by approximately 97%, peaking at over $9 billion in 2023. In contrast, Amneal's investment remained relatively stable, with a modest increase of about 57% over the same period. This stark difference highlights Eli Lilly's commitment to innovation, positioning it as a leader in the pharmaceutical industry. As the demand for new treatments grows, these investments could be pivotal in shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025